4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

4 - Structure Therapeutics Inc. (0001888886) (Issuer)

8-K - Structure Therapeutics Inc. (0001888886) (Filer)

424B5 - Structure Therapeutics Inc. (0001888886) (Filer)

424B5 - Structure Therapeutics Inc. (0001888886) (Filer)

8-K - Structure Therapeutics Inc. (0001888886) (Filer)

SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SCHEDULE 13G - Structure Therapeutics Inc. (0001888886) (Subject)

SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

10-Q - Structure Therapeutics Inc. (0001888886) (Filer)

SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the secu

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics. The gross proceeds to Structure Therapeutics from the offeri

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million of American depositary shares (ADSs), each representing three ordinary shares, or for certain investors that so choose, in lieu of ADSs, pre-funded warrants to purchase ordinary shares, represented by ADSs. All securities are being offered by Structure Therapeutics. In connection with the proposed offering,

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutic

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company's website at

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation anticipated by year-end 2025; second oral amylin receptor agonist (ACCG-3535) development candidate declared Strong financial position with cash, cash equivalents and short-term investments of $799.0 million as of September 30, 2025 SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus o

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in September. Cantor Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, September 3 at 3:55 p.m. ET Location:New York, NY   Morgan Stanley 23rd Annual Global Healthcare Conference Format:Fireside chat and 1x1 meetings Date/time:Wednesday, September 10 at 10:45 a.m. ET Location:New York, NY    The live and archived webcasts will

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phase 3 program Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 initiation anticipated by year-end 2025 Strong financial position with cash, cash equivalents and short-term investments of $786.5 million as of June 30, 2025 expected to fund projected operations and key clinical milestones through at least 2027 SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceu

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL. "The amylin receptor is rapidly gaining clinical validation as a key target in obesity, driven by encouraging data from injectable peptide programs. We believe ACCG-2671 is well-positioned and differentiated as an oral small molecule frontrunner that is expected to enter clinical development by the end of

SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June. Jefferies Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Thursday, June 5 at 8:10 a.m. ETLocation: New York, NY Goldman Sachs Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Wednesday, June 11 at 10:40 a.m. ETLocation: Miami, FL The live and archived webcasts of the fireside chats will be accessible from the compa

SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase

SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve

Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129

SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced that it has appointed Ted W. Love, M.D., to its Board of Directors. Dr. Love brings more than 30 years of experience in the biopharmaceuticals industry, and currently chairs the Biotechnology Innovation Organization (BIO) Board. He recently served as President and Chief Executive Officer of Global Blood Therapeutics until its acquisition by Pfizer in 2022. "Ted has a deep passion for making medicines accessible to all and has spent much of his acc

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutic

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company's website at

Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today

Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati

GSBR-1290 achieved a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% (p<0.0001) in the Phase 2a obesity study and up to 6.9% (p<0.0001) in the capsule to tablet PK study, in both cases at 12 weeks GSBR-1290 demonstrated generally favorable safety and tolerability results with low AE-related study discontinuations Pharmacokinetic data support dose proportional exposure and once-daily oral dosing of GSBR-1290 36-week Phase 2b study in obesity on track to begin in the fourth quarter of 2024 Company to host conference call today at 8:30 a.m. ET SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clin

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0% study discontinuation rate due to adverse events in obesity Topline Phase 2a data from first study in type 2 diabetes mellitus (T2DM) demonstrate significant reductions in hemoglobin A1c (HbA1c) and weight at 12 weeks Interim Phase 2a data from obesity cohort demonstrate significant reduction in weight at 8 weeks; full 12-week obesity data expected in second quarter 2024 with Phase 2b study initiation on track for second half 2024 Program update includes results from Japanese bridging study a

GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily dosing Topline data from Phase 2a type 2 diabetes cohort expected in latter half of fourth quarter 2023; topline data from obesity cohort now expected in the first half 2024 Phase 2b studies in type 2 diabetes and obesity planned for initiation in 2024 Company to host conference call today, September 29 at 8:30 a.m. ET SAN FRANCISCO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral sma

SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)